Related Experiment Video
Updated: Aug 15, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Applications of AmpliChip CYP450
1Jain PharmaBiotech, Basel, Switzerland. jain@pharmabiotech.ch
Molecular Diagnosis : a Journal Devoted to the Understanding of Human Disease Through the Clinical Application of Molecular Biology
|November 8, 2005
Summary
Pharmacogenetics, focusing on Cytochrome P450 (CYP) variants, is crucial for personalized medicine. CYP testing, like AmpliChip CYP450, aids in selecting optimal drug therapies and dosages for individual patients.
Area of Science:
- Pharmacogenetics
- Molecular Diagnostics
- Personalized Medicine
Background:
- Cytochrome P450 (CYP) enzymes, particularly CYP2D6 and CYP2C19, metabolize about 25% of prescription drugs.
- Understanding individual CYP metabolic status is vital for effective drug therapy and personalized medicine.
- The CYP system also plays a role in disease pathophysiology.
Purpose of the Study:
- To review the role of the CYP system in drug metabolism and disease.
- To describe technologies for assessing CYP status, focusing on the AmpliChip CYP450 test.
- To illustrate the application of CYP polymorphism testing in various drug categories.
Main Methods:
- Review of scientific literature on CYP enzymes and pharmacogenetics.
- Description of the AmpliChip CYP450 test, a microarray diagnostic for CYP2D6 and CYP2C19 polymorphisms.
- Analysis of drug metabolism pathways and therapeutic implications of CYP variants.
Main Results:
- The AmpliChip CYP450 is the first FDA-cleared DNA microarray test for analyzing CYP2D6 and CYP2C19 genetic variations.
- CYP testing guides drug selection and dosage for antidepressants, antipsychotics, immunosuppressants, and anticancer drugs.
- CYP testing has applications in toxicology and ADME profiling for drug development.
Conclusions:
- CYP testing, exemplified by AmpliChip CYP450, is a valuable tool for personalized medicine.
- This technology aids in optimizing pharmacotherapy by informing drug selection and dosage decisions.
- The clearance of AmpliChip CYP450 paves the way for future microarray-based diagnostic tests, advancing personalized medicine.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:16Drug Biotransformation: Overview
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...